COMPANY PROFILE

Neuromod Devices

Explore full profile

The standard-bearer for scientifically-proven tinnitus treatment.

IrelandFounded 2010Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2025

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Neuromod Devices

Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.

Read full description

We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control of their own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.

Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2010
Headquarters: Ireland
Employees: 64
Open positions: None listed
Dealroom signal: 62.3/100
Industry: Health
Sub-industry: BioTechnology, Medical Devices
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Neuromodulation and Neurostimulation, Chronic Disease, Non-Invasive medical devices and treatments, Spinout, biotech medtech and e-health, Digital Care, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning Neuromod Devices.

See all news

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Mar 2025	$11M	$83M	Fountain Healthcare Partners · Panakès Partners	↗
DEBTDebt	Apr 2023	$17M	—	European Investment Bank	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Neuromod Devices website traffic

Latest recorded traffic for Neuromod Devices is 300 monthly website visits, down 88.5% over the last three months. Neuromod Devices's team grew 4.9% over the past year.

Latest monthly visits300 3-month web change-88.5% 1-year team growth+4.9%

Monthly website visitsOct 2014–Oct 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MTMensia TechnologiesNon-invasive neurofeedback medical device for the treatment of ADHD and a number of other central nervous system disorders	Paris, France	Closed	1	$9.9M	$5.7M
RNRestorative NeurotechnologiesProducing wearable medical device in order to enhance the strength of the rehabilitation for cognitive disease or enhance sport performance	Palermo, Italy	Operational
GRGraphealGrapheal develops and manufactures true monolayer graphene on flexible substrates, enabling next-generation sustainable and cost-effective sensor platforms especially when coupled with IOTs	Grenoble, France	Operational
MEMedicsenNeedle-free drug delivery platform based on sonophoresis (ultrasounds) to replace needles and cannulas in the transdermal delivery of large molecules	Madrid, Spain	Operational
BIBioSerenityLeading global providers of remote diagnostic solutions	Paris, France	Operational
TITissiumDevelops biodegradable sealants and adhesives for wound closure in the field of minimally-invasive surgery	Paris, France	Operational
STSinaptica TherapeuticsClinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease	Cambridge, United States	Operational
ESETISENSE SASDeveloped a non-invasive cardiac and respiratory flow-metering technology to monitor cardiorespiratory function in a non-invasive way	Lyon, France	Operational